Abstract
There is ample evidence that immune-related processes in humans are under temporal regulation. The circadian variation of humoral and cellular immunity is well documented and appears to be hormonally modulated via the hypothalamic-pituitary-adrenal axis. In advanced melanoma, it has recently been demonstrated that systemic immunity is repolarized toward a global state of chronic inflammation (Th2 dominance) and appears to be governed by infradian biorhythms of cytokines and immune cell subsets, which extend beyond the 24-h circadian variability reported in healthy volunteers. It is suggested that synchronizing administration of lymphodepleting chemotherapy (temozolomide) with these endogenous (individualized) immune dynamics (biorhythms) in patients with advanced/metastatic melanoma improves clinical outcomes compared with temozolomide used in a conventional 'random delivery' fashion.
Original language | English (US) |
---|---|
Pages (from-to) | 1401-1406 |
Number of pages | 6 |
Journal | Future Oncology |
Volume | 8 |
Issue number | 11 |
DOIs | |
State | Published - Nov 2012 |
Keywords
- biorhythms
- cancer
- chemotherapy
- cytokine
- immunity
- infradian
- melanoma
ASJC Scopus subject areas
- Oncology
- Cancer Research